For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Molecular mechanisms of breast cancer tumours

SABCS 2008

10 - 14 Dec 2008

Published: 12 Jan 2009

Views: 15864

Rating:

Save

Dr. Kornelia Polyak, Dana-Farber Cancer Institute

Investigating breast cancer tumour evolution and therapeutic resistance

Related Videos

IMPRIME 1: Combination of pembrolizumab and a novel innate immune activator, Imp...

Dr Steven O'Day - John Wayne Cancer Institute, Santa Monica, USA

IMPRIME 1: Combination of pembrolizumab and a novel innate immune activator, Imprime PGG, in second-line mTNBC ( Dr Steven O'Day - John Wayne Cancer Institute, Santa Monica, USA )

I-SPY 2: Durvalumab in combination with olaparib and paclitaxel in high-risk HER...

Prof Lajos Pusztai - Yale Cancer Center, New Haven, USA

I-SPY 2: Durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer ( Prof Lajos Pusztai - Yale Cancer Center, New Haven, USA )

Treatment of advanced stage breast cancer

Dr Shona Nag - Sahyadri Hospitals, Pune, India

Treatment of advanced stage breast cancer ( Dr Shona Nag - Sahyadri Hospitals, Pune, India )

Shaping the future of metastasis - ecancer investigates

Monique Biryiana - ecancer Medical Reporter, Dr Chris Bakal - Dynamical Cell Sys...

Shaping the future of metastasis - ecancer investigates ( Monique Biryiana - ecancer Medical Reporter, Dr Chris Bakal - Dynamical Cell Systems Team Leader, Patricia Pascual Vargas - PhD Student )

Breast cancer highlights from ESMO 2019

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Breast cancer highlights from ESMO 2019 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Comment: Keynote 522 trial

Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy

Comment: Keynote 522 trial ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postme...

Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California )

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-po...

Prof George Sledge - Stanford Health Care, Stanford, USA

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer ( Prof George Sledge - Stanford Health Care, Stanford, USA )

Comment: CDK4/6 inhibitors in advanced breast cancer

Prof Nadia Harbeck - University of Munich, Munich, Germany

Comment: CDK4/6 inhibitors in advanced breast cancer ( Prof Nadia Harbeck - University of Munich, Munich, Germany )

More from ecancer